帕罗西汀联合坦度螺酮治疗慢性阻塞性肺疾病合并焦虑与抑郁老年患者的临床研究  

Clinical trial of paroxetine combined with tandospirone in the treatment of elderly patients with chronic obstructive pulmonary disease complicated with anxiety and depression

作　　者：屈蕾蕾[1] 胡杰亮[2] 刘丽君[1] 杨瑞 祁春阳 QU Lei-lei;HU Jie-liang;LIU Li-jun;YANG Rui;QI Chun-yang(Department of Respiratory and Critical Care Medicine,Baiyin First People,s Hospital,Baiyin 730900,Gansu Province,China;Department of Scientific Research,Baiyin First People,s Hospital,Baiyin 730900,Gansu Province,China)

机构地区：[1]白银市第一人民医院呼吸与危重症医学科,甘肃白银730900 [2]白银市第一人民医院科研科,甘肃白银730900

出　　处：《中国临床药理学杂志》2021年第13期1641-1644,共4页The Chinese Journal of Clinical Pharmacology

基　　金：甘肃省中医药科研立项课题基金资助项目(GZK-2019-83);白银市科技计划基金资助项目(2019YK-01)。

摘　　要：目的探讨帕罗西汀联合坦度螺酮对慢性阻塞性肺疾病(慢阻肺)合并焦虑、抑郁老年患者的疗效及安全性。方法将纳入的慢性阻塞性肺疾病合并焦虑、抑郁老年患者100例随机分为2组:对照组50例(用帕罗西汀2040 mg·d^(-1)治疗),试验组50例(用帕罗西汀2040 mg·d^(-1)联合坦度螺酮30 mg60 mg·d^(-1)治疗),均治疗4周。比较2组患者的临床疗效、焦虑自评量表(SAS)评分、抑郁自评量表(SDS)和第1秒用力呼气容积占预计值百分比(FEV_(1)%)和药物不良反应(ADR)的发生情况。结果对照组有效率为80.00%,低于试验组有效率94.00%,组间比较差异有统计学意义(P<0.05)。治疗4周后,试验组和对照组的SAS评分分别为(45.09±4.89)和(48.82±5.10)分;SDS评分分别为(45.62±4.37)和(49.43±4.52)分;FEV_(1)(%)分别为(84.35±10.24)%和(76.14±9.85)%,组间比较差异均有统计学意义(均P<0.05)。试验组和对照组的ADR发生率分别为34%和44%,组间比较差异无统计学意义(P>0.05)。结论帕罗西汀联合坦度螺酮对慢阻肺合并焦虑、抑郁老年患者的疗效显著,可以降低SAS、SDS,改善焦虑抑郁状态,提高肺功能和生存质量,且安全性高。Objective To investigate the clinical effect and safety of paroxetine combined with tandospirone in the treatment of elderly patients with chronic obstructive pulmonary disease complicated with anxiety and depression.Methods One hundred elderly patients with chronic obstructive pulmonary disease complicated with anxiety and depression will be included were randomly divided into two groups:control group with 50 patients were treated with paroxetine 20-40 mg·d^(-1);treatment group with 50 patients were treated with paroxetine 20-40 mg·d^(-1)combined with tandosterone 30-60 mg·d^(-1),2 groups were both treated for 4 weeks.The clinical efficacy,self-rating anxiety scale(SAS)scores,self-rating depression scale(SDS)scores,the percentage of forced expiratory volume in the first second(FEV_(1)%),and incidence of adverse drugs reaction(ADR)were compared between 2 groups.Results The effective rate of the control group(80.00%)was lower than the treatment group(94.00%),the difference was statistically significant(P<0.05).After 4 weeks of treatment,the SAS scores in treatment group and the control group were respectively(45.09±4.89)and(48.82±5.10)point,SDS scores were respectively(45.62±4.37)and(49.43±4.52)point,FEV_(1)(%)were respectively(84.35±10.24)%and(76.14±9.85)%,the differences of the factors were all statistically significant(all P<0.05).The total incidence of ADR in the treatment group and control group were 34%and 44%,there was no significant difference between the two groups(P>0.05).Conclusion Paroxetine combined with tandospirone has significant effect on elderly patients with chronic obstructive pulmonary disease complicated with anxiety and depression,which can reduce SAS and SDS,improve anxiety and depression,improve lung function and quality of life,and have high safety.

关 键 词：帕罗西汀 坦度螺酮 慢性阻塞性肺疾病 焦虑 抑郁 安全性评价 

分 类 号：R97[医药卫生—药品]